Cell Microarray Technology

Physiological system for detecting ligand-receptor interactions

Retrogenix’s unique cell microarray technology provides a fast, accurate and effective solution for discovering the human cell surface targets of antibodies, proteins, viruses and small molecules. This allows our global pharmaceutical clients to:

  • overcome the critical deconvolution step in phenotypic drug discovery
  • uncover novel, high quality and exploitable drug targets
  • explore off-target liabilities of lead candidates

Retrogenix’s biologically-relevant system detects specific interactions with a high degree of sensitivity. This unique tool uses proprietary arrays of expression vectors – encoding around 4,500 full-length human plasma membrane proteins – spotted onto slides. Human cells grown over the top become reverse-transfected resulting in over-expression of each respective plasma membrane protein at distinct slide locations. The test molecule is applied and specific binding analysed and confirmed using an appropriate detection system.

Technology Advantages

Retrogenix’s broad coverage extends across the full spectrum of known plasma membrane protein sub-classes including, amongst others: G protein coupled receptors (GPCRs), ion channels, drug transporters, Ig superfamily receptors, cytokines and growth factor receptors.

Keep reading to find out how our cell microarray technology compares to standard methods:

Keep reading

Case Studies

Retrogenix’s results are now supporting patent applications, appearing in peer-reviewed publications and being presented at international conferences. Our case studies highlight a selection of these projects providing further details on receptor identification, target deconvolution and specificity screening for biotherapeutics such as CAR T cells and antibodies.

Find out about how the Retrogenix Technology has been used:

Case Studies

Pfizer
The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
BioInvent
AstraZeneca
Bluebird Bio
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
MedImmune
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
…there was "no doubt" that the breakthrough in identifying EPCR was due to the Retrogenix screening tool.
Quote by Assistant Professor Thomas Lavstsen, University of Copenhagen. BioWorld Today, June 2013